Sanofi Signs US$2.26 B Deal with Start-Up DiCE Molecules to Develop Next-Generation Oral Therapeutics
By Heather Cartwright & Natasha Berry
Pharma Deals Review: Vol 2016 Issue 4 (Table of Contents)
Published: 13 Apr-2016
DOI: 10.3833/pdr.v2016.i4.2152 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Continuing its strategy of investing in early-stage start-ups as part of its Sunrise Initiative, Sanofi has entered into a 5-year collaboration with Stanford University spin-out DiCE Molecules to discover potential new oral therapies for up to 12 targets spanning disease areas of strategic interest to Sanofi...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS